MYLAN/MOVA GENERIC GLYBURIDE NEGOTIATIONS COULD ALLOW MYLAN PRODUCT TO REMAIN ON MARKET; MOVA PREVAILS IN INJUNCTION HEARING TO RESCIND ANDA APPROVAL
Mylan and Mova are negotiating to allow Mylan to continue to market a generic version of micronized glyburide (Pharmacia & Upjohn's diabetes therapy Glynase) following a federal court opinion in favor of Mova that would rescind Mylan's ANDA approval.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth